Affymetrix and BioDiscovery this week announced the availability of Nexus for OncoScan Software for the analysis of whole-genome copy number data generated from formalin-fixed, paraffin-embedded solid tumor samples using Affy's OncoScan FFPE Express 2.0 Service.
The offering is based on BioDiscovery's Nexus Copy Number software. The two companies said they intend to launch an updated version of the Nexus for OncoScan Software when Affy rolls out a kitted version of the assay later this year.
Using Affy's OncoScan service, customers can currently analyze highly degraded DNA in FFPE tumor samples. The company claimed that 30 cancer research institutes, including MD Anderson Cancer Center; the University of California, San Francisco; and the Huntsman Cancer Institute at the University of Utah, have all used the service.